Sharma, Ashish http://orcid.org/0000-0002-8550-9791
Kumar, Nilesh http://orcid.org/0000-0002-7439-2081
Parachuri, Nikulaa
Karanam, Dhatri
Kuppermann, Baruch D.
Bandello, Francesco http://orcid.org/0000-0003-3238-9682
Regillo, Carl D.
Article History
Received: 15 August 2021
Revised: 21 October 2021
Accepted: 21 October 2021
First Online: 30 October 2021
Competing interests
: Dr. Ashish Sharma: consultant for Novartis, Allergan, Bayer, and Intas. Baruch D. Kuppermann: clinical research: Alcon, Alimera, Allegro, Allergan, Apellis, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron, ThromboGenics; consultant: Alimera, Allegro, Allergan, Cell Care, Dose, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics, jCyte, Novartis, Ophthotech, Regeneron, Revana, Theravance Biopharma. Dr. Francesco Bandello: consultant: Allergan, Bayer, Boehringer- Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. Dr. Carl D Regillo: consultant: Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Notal, Merck, Shire-Takeda, Adverum, Graybug, and Eyepoint and receives research support from Allergan, Chengdu Kanghong, Genentech/Roche, Novartis, Kodiak, Iveric, and Adverum. Dr. Nilesh Kumar, Dr. Nikulaa Parachuri, and Dr. Dhatri Karanam: none.
Free to read: This content has been made available to all.